A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs Seasonal-influenza-virus-vaccine-high-dose+COVID-19-Vaccine-adjuvanted-Sanofi (Primary)
- Indications COVID 2019 infections; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 29 Nov 2024 Planned primary completion date changed from 6 Feb 2026 to 9 Feb 2026.
- 29 Nov 2024 Status changed from not yet recruiting to recruiting.
- 27 Nov 2024 New trial record